Efficacy and safety of agomelatine 25-50 mg/day versus escitalopram 10-20 mg/day in severe generalized anxiety disorder

Stein D.J. Khoo J.P. Van Ameringen D.M. Hoschl C., Ahokas A., Bauer M., Bitter I., Jarema M., Mosolov S., Vavrusova L., Picarel-Blanchot F., Matharan S., Olivier V.

Издание:

European Neuropsychopharmacology

Год издания:

2017

Номер:

Vol. 27. № 4

Страницы:

S1003

Язык:

English

Аннотация:

AIM OF THE ANALYSIS The present analysis assesses the 12-week efficacy and safety of agomelatine 25-50 mg versus escitalopram 10-20 mg in non-depressed outpatients with severe generalized anxiety disorder (GAD). METHOdS In this phase III, multicenter, international, randomized, double-blind, comparative trial, 523 patients were randomized into two parallel groups: agomelatine 25-50 mg (n=261) or escitalopram 10-20 mg (n=262). RESULTS Randomized patients had a mean age of 41 years, and 69% of them were female. All patients fulfilled DSM-IV diagnostic criteria for GAD and experienced functional impairment according to the Sheehan Disability Scale (SDS).

Добавил:

Администратор С.А.Т. 2018-03-13

Ключевые слова:

agomelatine, escitalopram, anxiety disorder, ,

Файл:

Скачать файл